Stay updated with breaking news from Company Codes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease - read this article along with other careers information, tips and advice on BioSpace
Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results - read this article along with other careers information, tips and advice on BioSpace
Published: Jul 29, 2021 NEW YORK, July 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Michael Rabinowitz to the newly created position of Chief Commercial Officer effective August 1, 2021. Mr. Rabinowitz will be responsible for Oramed's overall commercial strategy and execution. "As we move through the Phase III trials of our oral insulin, ORMD-0801, we are looking ahead towards the next step: comme...
Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities - read this article along with other careers information, tips and advice on BioSpace
Reimbursement proceedings with publicly funded health plans ready to commence MONTREAL, June 1, 2021 /PRNewswire/ - Valeo" or the " Company"), a Canadian pharmaceutical company, announced today that private payer health plans currently covering 80% of privately insured lives in Canada have agreed to provide reimbursement for Enerzair Breezhaler and Atectura Breezhaler. Enerzair Breezhaler and Atectura Breezhaler are two new innovative asthma therapies which have been approved for use in Canada. "Asthma therapies are largely covered by private payers representing 50% of the total market. Reim...